menu
    • menu
    [{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"Dynacure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Antisence Oligonucleotide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Flamingo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Flamingo Therapeutics \/ Dynacure","highestDevelopmentStatusID":"8","companyTruncated":"Flamingo Therapeutics \/ Dynacure"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"VLAIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Danvatirsen","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Flamingo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Flamingo Therapeutics \/ VLAIO","highestDevelopmentStatusID":"8","companyTruncated":"Flamingo Therapeutics \/ VLAIO"}]

    Find Clinical Drug Pipeline Developments & Deals by Flamingo Therapeutics

    Menu

    Flamingo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Flamingo Therapeutics

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Flamingo Therapeutics

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Danvatirsen,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : VLAIO

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio

                            Details : The funding will advance Flamingo's RNA-targeting oncology portfolio, including translational research for its lead clinical program, AZD9150 (danvatirsen) in Phase II in head and neck squamous cell carcinoma, and preclinical work on its LncRNA program t...

                            Brand Name : AZD9150

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 15, 2023

                            Lead Product(s) : Danvatirsen,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : VLAIO

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Flamingo Therapeutics

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Flamingo Therapeutics

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisence Oligonucleotide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Dynacure

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clini...

                            Details : The combined oncology company will advance Flamingo's lead programs, Danvatirsen (antisence oligonucleotide) in a Phase II trial PEMDA-HN in Head & Neck cancer (danvatirsen in combination with pembrolizumab) and other indications; and FTX-001 targeting M...

                            Brand Name : Danvatirsen

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : Antisence Oligonucleotide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Dynacure

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth